Скачать или смотреть Retreatment with R-CHOP-like therapy in patients with late relapse of DLBCL

Jean-Nicolas Champagne, MD, University of Montreal, Montreal, Canada, comments on a retrospective study of R-CHOP-like therapy in patients with late relapse of diffuse large B-cell lymphoma (DLBCL). The study found that patients who received a second round of R-CHOP-like therapy after a late relapse (defined as relapse after 24 months) had an overall response rate of 72%, with time to progression significantly increasing in patients who relapsed five years or more after their initial diagnosis. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.